Esperion Therapeutics Q3 2023 Earnings Report $2.46 +0.13 (+5.58%) (As of 12/17/2024 ET) Earnings HistoryForecast Esperion Therapeutics EPS ResultsActual EPS-$0.37Consensus EPS -$0.42Beat/MissBeat by +$0.05One Year Ago EPS-$0.81Esperion Therapeutics Revenue ResultsActual Revenue$33.97 millionExpected Revenue$30.84 millionBeat/MissBeat by +$3.13 millionYoY Revenue GrowthN/AEsperion Therapeutics Announcement DetailsQuarterQ3 2023Date11/7/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseESPR Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Esperion Therapeutics Earnings HeadlinesCantor Fitzgerald Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight RecommendationDecember 17 at 11:05 PM | msn.comEsperion initiated with an Overweight at Cantor FitzgeraldDecember 17 at 12:47 PM | markets.businessinsider.comMusk threatens Liberal’s fake “energy crisis”Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.December 18, 2024 | Porter & Company (Ad)Esperion Therapeutics' (ESPR) Buy Rating Reiterated at Needham & Company LLCDecember 16 at 2:24 AM | americanbankingnews.comEsperion’s Strategic Debt Refinancing Boosts Financial Stability and Investor AppealDecember 15 at 11:24 AM | markets.businessinsider.comEsperion Announces $210 Million Convertible Debt FinancingDecember 13, 2024 | globenewswire.comSee More Esperion Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Esperion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Esperion Therapeutics and other key companies, straight to your email. Email Address About Esperion TherapeuticsEsperion Therapeutics (NASDAQ:ESPR), a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.View Esperion Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
